Abstract
Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 106-112 |
| Number of pages | 7 |
| Journal | Otolaryngology - Head and Neck Surgery (United States) |
| Volume | 155 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 1 2016 |
| Externally published | Yes |
Fingerprint
Keywords
- biomarkers
- cMet
- cyclin D1
- EGFR
- head and neck cancer
- p16
- sarcomatoid
- spindle cell
ASJC Scopus subject areas
- Surgery
- Otorhinolaryngology
Cite this
Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. / Rosko, Andrew J.; Birkeland, Andrew C.; Wilson, Kevin F.; Muenz, Daniel G.; Bellile, Emily; Bradford, Carol R.; McHugh, Jonathan B.; Spector, Matthew E.
In: Otolaryngology - Head and Neck Surgery (United States), Vol. 155, No. 1, 01.07.2016, p. 106-112.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck
AU - Rosko, Andrew J.
AU - Birkeland, Andrew C.
AU - Wilson, Kevin F.
AU - Muenz, Daniel G.
AU - Bellile, Emily
AU - Bradford, Carol R.
AU - McHugh, Jonathan B.
AU - Spector, Matthew E.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.
AB - Objective To determine biomarkers of recurrence and survival in patients with spindle cell variant squamous cell carcinoma (SpSCC) of the head and neck. Study Design Retrospective case control study. Setting Tertiary academic center. Subjects and Methods Thirty-two SpSCC patients (mean age, 68.8) between 1987 and 2009 were identified and reviewed. A tissue microarray (TMA) was constructed from tumor specimens. Tumor biomarkers under study included p16, epidermal growth factor receptor (EGFR), p53, EZH2, cyclin D1, CD104, HGFa, p21, and cMET. An additional TMA was constructed from patients with non-SpSCC oral cavity squamous cell carcinoma for comparative purposes. The main outcomes were overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS). Results In the SpSCC cohort, tumors positive for cMet had worse OS (P <.001). Patients positive for cMet (P =.007), cyclin D1 (P =.019), and p16 (P =.004) had worse DSS. Recurrence-free survival was also worse in patients with tumors positive for cMet (P =.037), cyclin D1 (P =.012), and p16 (P <.001). Compared with the oral cavity cohort, there was a significantly larger proportion of patients in the SpSCC group with tumors staining positive for cMet and a lower proportion of tumors positive for cyclin D1. Conclusion cMet, cyclin D1, and p16 are predictive tumor biomarkers for risk of recurrence and worse DSS in patients with SpSCC.
KW - biomarkers
KW - cMet
KW - cyclin D1
KW - EGFR
KW - head and neck cancer
KW - p16
KW - sarcomatoid
KW - spindle cell
UR - http://www.scopus.com/inward/record.url?scp=84976876902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976876902&partnerID=8YFLogxK
U2 - 10.1177/0194599816636612
DO - 10.1177/0194599816636612
M3 - Article
C2 - 26980915
AN - SCOPUS:84976876902
VL - 155
SP - 106
EP - 112
JO - Otolaryngology - Head and Neck Surgery (United States)
JF - Otolaryngology - Head and Neck Surgery (United States)
SN - 0194-5998
IS - 1
ER -